(Circulation. 1999;100:1438-1442.)
© 1999 American Heart Association, Inc.
Basic Science Reports |
Total Complement Inhibition
An Effective Strategy to Limit Ischemic Injury During Coronary Revascularization on Cardiopulmonary Bypass
From the Department of Cardiothoracic Surgery, Boston University School of Medicine and Boston Medical Center, Boston, Mass.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background—Activation of complement during revascularization of ischemic myocardium accentuates myocardial dysfunction. Soluble human complement receptor type 1 (sCR1) is a potent inhibitor of complement, as are heparin-bonded (HB) cardiopulmonary bypass (CPB) circuits. This study sought to determine whether total complement inhibition with the combination of sCR1 and HB-CPB limits damage during the revascularization of ischemic myocardium.
Methods and Results—In 40 pigs, the second and third diagonal
coronary arteries were occluded for 90 minutes, followed by 45
minutes of cardioplegic arrest and 180 minutes of reperfusion. In 10
pigs, sCR1 (10 mg/kg) was infused 5 minutes after the onset of
coronary occlusion (sCR1), 10 received HB-CPB only (HB-CPB), 10
received sCR1 and HB-CPB (sCR1+HB), and 10 received neither sCR1 or
HB-CPB (unmodified). Addition of sCR1 to the HB group resulted in less
myocardial tissue acidosis (
pH=-0.72±0.03 for unmodified;
-0.46±0.05* for HB; -0.18±0.04*
for sCR1; -0.13±0.01* for
sCR1+HB), better recovery of wall motion scores (4=normal to
-1=dyskinesia; 1.67±0.17 for unmodified; 2.80±0.08* for HB;
3.35±0.10* for sCR1; 3.59±0.08* for sCR1+HB), less lung water
accumulation (5.46±0.28% for unmodified; 2.39±0.34%* for HB;
1.22±0.07%* for sCR1; 1.24±0.13%* for sCR1+HB), and smaller
infarct size (area necrosis/area risk=44.6±0.7% for unmodified;
33.2±1.9%* for HB; 19.0±2.4%* for sCR1; 20±1.0%* for sCR1+HB)
(*P<0.05 versus unmodified; P<0.05
versus unmodified and HB groups).
Conclusions—Total complement inhibition with sCR1 and sCR1+HB circuits optimizes recovery during the revascularization of ischemic myocardium.
Key Words: heparin • myocardial infarction
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Activation of the complement system during cardiopulmonary bypass (CPB) can result in postoperative myocardial dysfunction and increased lung water accumulation, which increases morbidity and prolongs hospital stay.1 2 Interventions that lower levels of complement activation during CPB may contribute to better patient outcomes after cardiac surgery.
Recent advances in heparin bonding and coating techniques have resulted in development of heparin-bonded (HB) CPB circuits, which have been shown to reduce complement levels by mechanically rendering the foreign surface of the CPB circuit inaccessible to the adsorption of complement.3 Our experimental and clinical studies have shown that these circuits limit myocardial necrosis, minimize blood loss and the need for blood products, and contribute to better patient outcomes after both elective and emergent cardiac surgery.4 5 6 HB coating, however, cannot completely inhibit complement activity because it cannot prevent the activation that occurs on the gas-surface interface of the CPB circuit7 and the activation of complement that occurs during regional ischemia.8 Hence, use of a complement inhibitor in addition to HB circuits might further improve their biocompatibility and limit ischemic damage.
Soluble human complement receptor type I (sCR1), a recombinant form of human complement receptor, is a potent inhibitor of both the classic and alternative pathways of complement activation.9 It has been shown to reduce infarct size in rats and limit reperfusion edema after lung transplants in the pig.9 10 In a recent study using a porcine model of acute coronary occlusion and reperfusion with cardioplegic arrest on CPB, we demonstrated that pretreatment with sCR1 significantly decreased infarct size and preserved regional wall motion.11
This experimental study was therefore undertaken to determine whether achieving total complement inhibition with a combination of sCR1 and HB-CPB would limit myocardial damage during the revascularization of acutely ischemic myocardium.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Randomization
Forty pigs were entered into the study and randomized to receive HB circuits, sCR1, sCR1+HB circuits, or no sCR1 or HB circuits (unmodified). Four pigs were excluded from the study: 2 had bilateral lobar pneumonia, 1 had pericarditis, and 1 developed intractable hypotension after anesthesia before coronary occlusion.
Preparation
Adult pigs (34 to 38 kg) were premedicated with ketamine
(15 mg/kg IM) and xylazine (0.5 mg/kg IM), anesthetized with
-chloralose (75 mg/kg), and placed on positive-pressure endotracheal
ventilation. After a median sternotomy and systemic heparinization (3
mg/kg), the second and third diagonal branches just distal to the
takeoff of the left anterior descending artery were occluded with
snares for 90 minutes. Pigs were then placed on CPB, followed by 45
minutes of multidose, antegrade/retrograde, cold-blood cardioplegic
arrest (potassium 25 mEq/L, hematocrit 20%, pH 7.6, temperature
4°C.) supplemented with topical hypothermia. After the aortic cross
clamp was removed, the coronary snares were released, and all
hearts were reperfused for 180 minutes on CPB at 37°C.
Treatment Groups
Unmodified Group
Ten pigs received neither sCR1 or HB circuits. CPB was
instituted by use of noncoated oxygenators and tubing (Membrane
Oxygenator, Sarnes Inc).
HB Group
No sCR1 was given to 10 pigs, but they received a completely
heparinized CPB circuit (Duraflo II heparin-coated circuit,
Baxter-Bentley Laboratories Inc). This included heparin coating of all
cannulas, arterial filters, and the cardiotomy
reservoir.
sCR1 Group
sCR1 (10 mg/kg IV, Avant Immunotherapeutics, Inc) was infused in
10 pigs over 30 minutes, beginning 5 minutes after the coronary
arteries were snared. This plasma concentration of sCR1 has previously
been shown to prevent complement activation in a porcine
model.11 These pigs received nonbonded CPB circuits.
sCR1+HB Group
Ten pigs received both sCR1 and HB-CPB circuits.
Measurements and Statistical Analyses
Total hemolytic complement activity was determined by a
modification of the method of Mayer.12 All complement
titers were expressed as a percentage of preischemic
values. Previous in vitro studies have demonstrated that human sCR1 is
able to completely inactivate both the classic and
alternative pathways of porcine complement.13 The
concentrations of sC5b-9 in pig plasma samples, referred to as C5b-9 in
the text, were determined by use of a dual monoclonal antibody enzyme
immunoassay similar to a previously published method.14
The monoclonal antibodies are specific for human C9 neoantigen (clone
aE11, Dako) and human C7 (Quidel) and were demonstrated to cross-react
with components of activated porcine complement. Increased
concentrations of C5b-9 are reported in arbitrary units per milliliter
and directly reflect complement activation in vivo. Two data points
from a single unmodified pig were excluded as statistical outliners
(>5 SD).
Myocardial tissue pH was measured with a pH probe (Khuri Tissue Ischemia Monitor, Vascular Technology Inc) and standardized according to myocardial temperature as previously described.15 pH values were expressed as the change in pH from preischemic values, recorded for each experiment, and then averaged for all experimental groups.
Echocardiographic short- and long-axis sections were used to determine wall motion changes in the area of risk with previously described techniques.15 A numerical score was used (4=normal, 3=mild hypokinesis, 2=moderate hypokinesis, 1=severe hypokinesis, 0=akinesis, -1=dyskinesia) to indicate the degree of wall motion abnormalities. The sections were interpreted by an experienced echocardiographer in a blinded fashion, and the scores were averaged for coronary occlusion and reperfusion periods for all experimental groups.
Lung water accumulation was assessed by use of wet-to-dry-weight ratios. Lung samples were excised with a stapler before CPB and after 3 hours of reperfusion. Lung tissue was weighed before and after 48 hours of incubation at 100°C. Results were expressed as the percentile weight gain from pre-CPB values for each experiment and then averaged for each group.
The areas of risk and necrosis were determined by histochemical staining techniques with triphenyltetrazolium chloride (Sigma Chemical Co) as described in our previous study.15 Stained myocardial slices were planimetered to obtain the area of risk compared with the total left ventricular mass and the percent area of infarct in that area of risk.
All values represent mean±SE. Differences in measurements between the various groups and across time were assessed by repeated measurements of ANOVA. StatView 4.5 (Abacus Concepts Inc) was used to compute these analyses. Data were considered significant at P values less than 0.05.
All pigs received humane care in compliance with the Principles of Laboratory Animal Care formulated by the National Society for Medical Research and the Guide for the Care and Use of Laboratory Animals prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH publication 86-23, revised 1985).
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Serum Complement Activity
Total hemolytic complement activity (CH50) is shown in Figure 1
. After 90 minutes of
coronary occlusion, CH50 values were
3.30±0.3% of preischemic values in sCR1 animals and
6.4±1.2% in the sCR1+HB group (both P<0.01 versus the
unmodified and HB groups). This indicated that virtually no hemolytic
complement activity was present in sCR1-treated pigs during
coronary occlusion. After 180 minutes of reperfusion on CPB,
CH50 levels were only 3.2±0.6% in sCR1 pigs and
3.5±1.0% in sCR1+HB pigs compared with 18.0±2.5% in the unmodified
and 23.0±2.9% in the HB group (P<0.01 versus sCR1 and
sCR1+HB).
|
Figure 2 summarizes the C5b-9 levels
during coronary occlusion and reperfusion on CPB. Before
coronary occlusion, there was no difference in C5b-9 levels
among the 4 groups. After 90 minutes of coronary occlusion,
C5b-9 levels decreased significantly in the sCR1 (11.6±3.3 versus
2.8±1.9 U/mL, P<0.001) and sCR1+HB (13.9±5.1 versus
0.0±0.0 U/mL, P<0.0001) groups. In contrast, C5b-9 levels
increased significantly in the unmodified (12.6±4.1 versus 20.4±8.9
U/mL, P<0.01) and HB (8.4±1.6 versus 25.5±5.7 U/mL,
P<0.01) groups. C5b-9 levels continued to rise
significantly in the unmodified group and reached its highest levels
180 minutes after reperfusion on CPB (73.5±13.2 U/mL). C5b-9 levels
increased only slightly during CPB in the HB group and were
significantly lower than the unmodified group after 180 minutes of
reperfusion (33.3±2.9 U/mL, P<0.01 versus the unmodified
group). Hearts treated with sCR1 and sCR1+HB-CPB had virtually no
circulating C5b-9 after 180 minutes of reperfusion.
|
Myocardial Tissue pH
Before coronary occlusion, myocardial tissue pH was
similar in all groups (7.32±0.04 for unmodified, 7.31±0.05 for HB,
7.29±0.04 sCR1, and 7.33±0.05 for sCR1+HB; P=NS). The
changes in pH after coronary occlusion are shown in Figure 3. Hearts treated with sCR1 had
significantly less tissue acidosis than those in the unmodified and HB
groups after 90 minutes of coronary occlusion
(pH=-0.85±0.03 for unmodified, -0.70±0.05 for HB
[P<0.05 versus unmodified], -0.30±0.05 for sCR1
[P<0.01 versus unmodified and HB], and -0.27±0.04 for
sCR1+HB [P<0.01 versus unmodified and HB]). After 180
minutes of reperfusion, HB hearts had significantly less tissue
acidosis compared with the unmodified group (pH, -0.72±0.03 for
unmodified versus -0.46±0.05 HB; P<0.03). The least
tissue acidosis was seen in the sCR1 (-0.18±0.04, P<0.01
versus unmodified and HB groups) and sCR1+HB (-0.13±0.04,
P<0.01 versus unmodified and HB groups) groups.
|
Wall Motion Scores
Wall motion scores for the area at risk are summarized in Figure 4. Ninety minutes of coronary
occlusion resulted in significant depression in wall motion scores in
both the unmodified (1.20±0.16, P<0.001 versus
preischemia) and HB (2.03±117, P<0.001 versus
preischemia) groups. In contrast, wall motion scores were
significantly higher in both the sCR1 and sCR1+HB groups (3.30±0.14
and 3.15±0.07, P<0.05 versus unmodified and HB groups).
Wall motion remained depressed in the unmodified hearts after 180
minutes of reperfusion but improved significantly in the HB group
(1.67±0.17 versus 2.80±0.08, P<0.05). However, the best
preservation of wall motion scores were seen in both the sCR1 and
sCR1+HB groups (3.35±0.10 versus 3.59±0.08, P<0.05 versus
both the unmodified and HB groups).
|
Lung Water Content and Infarct Size
The greatest accumulation of lung water occurred in the unmodified
group (5.46±0.28%). Although pigs treated with HB circuits had
significantly less water accumulation (2.39±0.34%, P<0.01
versus unmodified), the least water accumulation was seen in the sCR1
and sCR1+HB groups (1.22±0.07% and 1.24±0.13%, both
P<0.01 versus the unmodified and HB groups).
The area of myocardium at risk was similar in all groups (17.2±1.3% for unmodified, 16.5±0.9% for HB, 17.1±1.4% for sCR1, and 16.8±1.9% for sCR1+HB; P=NS). The amount of myocardial necrosis in the area at risk was greatest in the unmodified group (44.6±0.7%). Hearts treated with HB circuits alone had a significantly lower area of necrosis (33.2±1.89%, P<0.01 versus unmodified). The lowest area of necrosis was seen in the sCR1 and sCR1+HB groups (19.0±2.4 and 20.0±1.0, P<0.01 versus both the unmodified and HB groups).
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Growing evidence suggests that the inflammatory response that results from complement activation during CPB contributes to postoperative myocardial dysfunction and poor clinical outcomes.16 17 Seghaye and colleagues18 noted a strong correlation between complement activation and post-CPB multisystemic organ failure in children. Hennein and coworkers19 noted that elevated levels of the proinflammatory cytokines interleukin-6 and interleukin-8 after CPB were associated with new wall motion abnormalities after coronary artery bypass surgery.
C5b-9 is an important mediator of ischemic tissue injury and can directly result in myocardial dysfunction by altering intracellular Ca2+ and creating water and electrolyte imbalances in the myocyte.20 Increased levels of C5b-9 have been observed in the plasma of patients after an acute myocardial infarction and can be seen deposited in myocardial and endothelial cells in infarcted tissue and after reperfusion of ischemic myocardium.21 Formation of C5b-9 directly alters endothelial function by creating transmembrane channels that may ultimately result in cell lysis.9 Even nonlytic amounts of C5b-9 can result in the release of oxygen free radicals, prostaglandins, and leukotrienes and secretion of cytokines.22 Complement activation and C5b-9 formation have also been shown to upregulate the leukocyte adherence protein P-selectin on endothelial cells.23 P-selectin is necessary for leukocyte endothelial cell adherence and subsequent transendothelial migration. Hence, complement activation may also play an important role in transcellular migration of leukocytes during ischemia and reperfusion.
HB-CPB circuits have been shown to lower complement levels, decrease neutrophil activation, and reduce serum levels of interleukin-6 and interleukin-8.1 2 24 In our porcine model of acute coronary occlusion and reperfusion with cardioplegic arrest on CPB, we demonstrated that HB circuits preserved regional wall motion, minimized tissue acidosis and lung edema, and reduced infarct size.4 Our experimental findings were corroborated by several clinical studies. Jansen and coworkers2 measured C5a and C5b-9 levels in patients with and without HB circuits undergoing coronary bypass surgery. Although C5a and C5b-9 levels were significantly elevated from pre-CPB levels in both groups, they were lower in the HB patients. HB patients had significantly better recovery scores that reflected fluid balance, weight gain, and postoperative intubation time. In a prospective clinical study involving 234 patients undergoing CABG, patients treated with HB circuits had a lower incidence of myocardial infarction, less need for inotropic support, a lower incidence of prolonged ventilation, and fewer postoperative complications.5 In a recent study involving 206 patients undergoing emergent CABG, patients treated with HB circuits required fewer homologous donor units and less inotropic support and had a lower incidence of perioperative myocardial infarctions and a shorter duration of ventilatory support, ICU, and hospital stays.6
Another method of decreasing complement activation is the use of
soluble inhibitors. sCR1 exerts its biologic actions by
binding C3b and C4b to distinct sites, displacing the catalytic
subunits from C3 and C5 convertases, and acting as a cofactor in
promoting the degradation of C3b and C4b by factor I.9
By inhibiting complement activation by both the classic and alternative
pathways, sCR1 directly inhibits C5b-9 production and
indirectly inhibits the generation of interleukin-8, which has been
associated with the "capillary-leak syndrome" seen in post-CPB
patients.25 Although HB circuits result in significantly
less complement activation than non-HB circuits, a large amount of
complement is still generated. This is partly because heparin-coating
techniques cannot inhibit the complement activation that occurs at the
gas-surface interface. Generation of C3a is dependent on both the size
of the gas and biomaterial surfaces.26 Larsson and
coworkers7 showed the advantages of sCR1 in inhibiting
both gas and biomaterial surfaces in artificial conditions resembling a
CPB circuit. The addition of sCR1 to whole blood in tubing loops
inhibited the production of both C3a and C5b-9. In contrast to
C5b-9, which was almost completely inhibited by sCR1, 
30% of C3a
was unaffected. The results of this study strongly suggested that the
addition of a complement inhibitor such as sCR1 could
further improve the biocompatibility of HB-CPB circuits.
Our study confirms previous investigations showing that periods of regional ischemia can activate the complement cascade.8 Levels of C5b-9 were twice as great in the unmodified and HB groups after 90 minutes of coronary occlusion and 3.5 times higher than preischemic levels in the unmodified group after 180 minutes of CPB. The highest levels of C5b-9 were associated with the greatest lung water accumulation, poorest recovery of wall motion, most tissue acidosis, and largest infarct size. Although HB circuits decreased the activation of C5b-9 on CPB, the levels of complement were significantly higher than the sCR1-treated animals, and the recovery was not as good. The addition of sCR1 to the HB-treated pigs virtually abolished all complement activation and resulted in more complete recovery of ischemic damage. Because equal concentrations of heparin (3 mg/kg) were used in all study groups, heparin alone could not be responsible for the total complement inhibition seen in the sCR1+HB groups.
Although both sCR1 and sCR1+HB-CPB groups had similar recovery of regional wall motion and identical areas of infarct size, we continue to advocate the use of HB-CPB circuits despite the beneficial effects of sCR1 alone. HB circuits by themselves provide benefits unrelated to decreased complement activation that have resulted in less blood loss, have minimized the need for blood products, and have decreased the incidence of myocardial infarctions and strokes.5 6 In contrast, there is no evidence that sCR1 alone will decrease perioperative blood loss and the need for blood products.
Our data show that strategies that result in more complete inhibition of complement activation result in the least myocardial damage during the revascularization of acutely ischemic myocardium. The addition of sCR1 to HB-CPB and non–HB-CPB circuits will help decrease the deleterious effects of the increased inflammatory response associated with CPB. Inhibiting C5b-9 activation may better preserve endothelial function and prevent the accumulation of lung water and systemic weight gain that contribute to prolonged ventilatory support, myocardial dysfunction, and longer hospital stays. Clinical trials are being planned to determine whether the beneficial experimental results using the strategy of total complement inhibition with sCR1 and HB circuits will result in less morbidity and mortality in patients undergoing cardiac surgical procedures on CPB.
|
Acknowledgments |
|---|
This work was supported in part by a grant from Avant Immunotherapeutics, Inc, Needham, Mass.
|
Footnotes |
|---|
Reprint requests to Harold L. Lazar, MD, Department of Cardiothoracic Surgery, Boston Medical Center, 88 E Newton St, B-404, Boston, MA 02118.
Received March 5, 1999; revision received May 18, 1999; accepted May 26, 1999.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Fosse E, Mollnes TE, Ingvaldsen B. Complement activation during major operations with or without cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1987;93:860–866.[Abstract]
2.
Jansen PGM, Velthuis H, Huybregts RAJM, Paulus R,
Bulder ER, Spoel HI, Bezemer PD, Slaats EH, Eissman L, Wildevuur CRH.
Reduced complement activation and improved postoperative
performance after cardiopulmonary bypass with
heparin-coated circuits. J Thorac Cardiovasc Surg. 1995;110:829–834.
3. Videm V, Mollnes TE, Garred P, Svennevig JL. Biocompatibility of extracorporeal circulation: in vitro comparison of heparin-coated and uncoated oxygenator circuits. J Thorac Cardiovasc Surg. 1991;101:654–660.[Abstract]
4.
Lazar HL, Zhang X, Hamasaki T, Memmelo CA, Treanor P,
Rivers S, Aldea GS, Bernard SA, Shemin RJ. Heparin-bonded circuits
decrease myocardial ischemic damage: an experimental study.
Ann Thorac Surg. 1997;63:1701–1705.
5.
Aldea GS, Doursounian M, O'Gara P, Shapira OM, Lazar
HL, Shemin RJ. Heparin-bonded cardiopulmonary bypass
circuits and a reduced anticoagulation in patients undergoing primary
CABG: a prospective randomized study. Ann Thorac Surg. 1996;62:410–418.
6. Aldea GS, Lilly K, Gaudiani JM, O'Gara P, Stein D, Zao Y, Treanor P, Osman A, Shapira OM, Lazar HL, Shemin RJ. Heparin-bonded circuits improve clinical outcomes in emergency coronary artery bypass grafting. J Card Surg. 1997;12:389–397.[Medline] [Order article via Infotrieve]
7. Larsson R, Elgue G, Larsson A, Ekdahl KN, Nilsson UR, Nilsson B. Inhibition of complement activation by soluble recombinant CR1 under conditions resembling those in a cardiopulmonary circuit: reduced up-regulation of CD11b and complete abrogation of binding of PMNs to the biomaterial surface. Immunopharmacology. 1997;38:119–127.[Medline] [Order article via Infotrieve]
8.
Kagiyama A, Savage HE, Michael LH, Hanson G, Entman
ML, Rossen RD. Molecular basis of complement activation in
ischemic myocardium: identification of specific
molecules of mitochondrial origin that bind human C1a and fix
complement. Circ Res. 1989;64:607–615.
9.
Weisman HF, Bartow T, Leppo MK, Marsh HC, Carson GR,
Concino MF, Boyle MP, Roux KH, Weisfeldt ML, Fearon DT. Soluble human
complement receptor type I: in vivo inhibitor of complement
suppressing post-ischemic myocardial inflammation and necrosis.
Science. 1990;249:146–151.
10.
Schmid RA, Zollinger A, Singer T, Hillinger S,
Leon-Wyss JR, Schob OM, Hogasen K, Zund G, Patterson GA, Weder W.
Effect of soluble complement receptor type I on reperfusion edema and
neutrophil migration after lung allotransplantation in swine.
J Thorac Cardiovasc Surg. 1998;116:90–97.
11.
Lazar H L, Hamasaki T, Bao Y, Rivers S, Bernard SA,
Shemin RJ. Soluble complement receptor type I limits damage during
revascularization of ischemic
myocardium. Ann Thorac Surg. 1998;65:973–977.
12. Mayer MM. Complement and complement fixation. In: Kobat EA, Mayer MM, eds. Experimental Immunochemistry. Springfield, Ill: Charles C Thomas; 1961:133.
13. Gillinov AM, DeValeria PA, Winkelstein JA, Wilson I, Curtis WE, Shaw D. Complement inhibition with soluble complement receptor type I in cardiopulmonary bypass. Ann Thorac Surg. 1993;55:619–624.[Abstract]
14. Jansen JG, Hogasen K, Mollnes TE. Extensive complement activation in hereditary porcine membranoproliferative glomerulonephritis type-II (porcine dense deposit disease). Am J Pathol. 1993;143:1356–1365.[Abstract]
15. Lazar HL, Yang XM, Rivers S, Treanor P, Shemin RJ. Role of percutaneous bypass in reducing infarct size after revascularization for acute coronary insufficiency. Circulation. 1991;84:416–421.
16. Kirklin JK, Westaby S, Blackstone EH, Kirklin JW, Chenowith DE, Pacifico AD. Complement and the damaging effects of cardiopulmonary bypass. N Engl J Med. 1988;318:408–414.[Abstract]
17. Salama A, Hugo F, Heinrich D. Deposition of terminal C5b-9 complement complexes on erythrocytes and leukocytes during cardiopulmonary bypass. N Engl J Med. 1988;318:408–414.
18. Seghaye MC, Duchateau J, Gravitz RG, Faymonville ML, Messmer BJ, Buro-Rathsmann K. Complement activation during cardiopulmonary bypass in infants and children. J Thorac Cardiovasc Surg. 1993;106:978–987.[Abstract]
19.
Hennein HA, Ebba H, Rodriguez JPL. Relationship of the
proinflammatory cytokines to myocardial ischemia and
dysfunction after uncomplicated coronary
revascularization. J Thorac Cardiovasc
Surg. 1994;108:626–635.
20.
Berger HJ, Taratuska A, Smith TW, Halperin JA.
Activated complement directly modifies the performance
of isolated heart muscle cells from guinea pig and rat. Am J
Physiol. 1993;265:H267–H272.
21. Langlis PF, Gawryl MS. Detection of the terminal complement complex in patient plasma following acute myocardial infarction. Atherosclerosis. 1988;70:95–105.[Medline] [Order article via Infotrieve]
22. Seeger W, Suttrop N, Hellwig A, Bhakdi S. Non-lytic terminal complement complexes may serve as calcium gates to elicit leukotriene by generation in human polymorphonuclear leukocytes. J Immunol. 1986;150:1286–1294.[Abstract]
23. Mulligan MS, Polley MJ, Bayer RJ, Nunn MF, Paulson JC, Ward PA. Neutrophil-dependent acute lung injury: requirement for P-selectin (GMP-140). J Clin Invest. 1992;90:1600–1607.
24. Videm V, Svennewig JL, Fosse E, Semb G, Osterud A, Mollnes TE. Reduced complement activation with heparin coated oxygenator and tubings in coronary bypass operations. J Thorac Cardiovasc Surg. 1992;103:806–813.[Abstract]
25.
Finn A, Morgan BP, Rebuck N, Klein N, Rogers CA, Hibbs
M. Effects of inhibition of complement activation using recombinant
soluble complement receptor I on neutrophil CD 11B/CD18 and
L-selectin expression and release of interleukin-8 and
elastase in simulated cardiopulmonary bypass. J
Thorac Cardiovasc Surg. 1996;111:451–459.
26. Nilsson VR, Nilsson B. Chandler loops as a model for cardiopulmonary bypass circuits: effects of soluble and surface conjugated heparin. J Clin Immunol. 1996;16:223–230.
This article has been cited by other articles:
 |
|
 |
|
  Y. Banz, R. Rieben, C. Zobrist, P. Meier, S. Shaw, J. Lanz, T. Carrel, and P. Berdat Addition of dextran sulfate to blood cardioplegia attenuates reperfusion injury in a porcine model of cardiopulmonary bypass Eur. J. Cardiothorac. Surg., September 1, 2008; 34(3): 653 - 660. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Banz, O. M. Hess, S. C. Robson, E. Csizmadia, D. Mettler, P. Meier, A. Haeberli, S. Shaw, R. A. Smith, and R. Rieben Attenuation of myocardial reperfusion injury in pigs by Mirococept, a membrane-targeted complement inhibitor derived from human CR1 Cardiovasc Res, December 1, 2007; 76(3): 482 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M Carter Inflammation, thrombosis and acute coronary syndromes Diabetes and Vascular Disease Research, October 1, 2005; 2(3): 113 - 121. [Abstract] [PDF]
|
|
|
|
 |
|
 L. J. Thomas, K. Panneerselvam, D. T. Beattie, M. D. Picard, B. Xu, C. W. Rittershaus, H. C. Marsh Jr., R. A. Hammond, J. Qian, T. Stevenson, et al. Production of a complement inhibitor possessing sialyl Lewis X moieties by in vitro glycosylation technology Glycobiology, October 1, 2004; 14(10): 883 - 893. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. L. Lazar, P. M. Bokesch, F. van Lenta, C. Fitzgerald, C. Emmett, H. C. Marsh Jr, U. Ryan, and OBE and the TP10 Cardiac Surgery Study Group Soluble Human Complement Receptor 1 Limits Ischemic Damage in Cardiac Surgery Patients at High Risk Requiring Cardiopulmonary Bypass Circulation, September 14, 2004; 110(11_suppl_1): II-274 - II-279. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. T. Lappegard, M. Fung, G. Bergseth, J. Riesenfeld, J. D. Lambris, V. Videm, and T. E. Mollnes Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation Ann. Thorac. Surg., March 1, 2004; 77(3): 932 - 941. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Chong, C. R. Hampton, and E. D. Verrier Microvascular Inflammatory Response in Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2003; 7(3): 333 - 354. [Abstract] [PDF]
|
|
|
|
 |
|
 I. Risnes, T. Ueland, R. Lundblad, T. E. Mollnes, S. T. Baksaas, P. Aukrust, and J. L. Svennevig Changes in the cytokine network and complement parameters during open heart surgery Interactive CardioVascular and Thoracic Surgery, March 1, 2003; 2(1): 19 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. I Flom-Halvorsen, E Ovrum, F Brosstad, G Tangen, M A. Ringdal, and R Oystese Effects of two differently heparin-coated extracorporeal circuits on markers for brain and myocardial dysfunction Perfusion, September 1, 2002; 17(5): 339 - 345. [Abstract] [PDF]
|
|
|
|
|
|
H. L. Lazar, Y. Bao, S. Rivers, and S. A. Bernard Pretreatment with angiotensin-converting enzyme inhibitors attenuates ischemia-reperfusion injury Ann. Thorac. Surg., May 1, 2002; 73(5): 1522 - 1527. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-C. Hsu Heparin-coated cardiopulmonary bypass circuits: current status Perfusion, September 1, 2001; 16(5): 417 - 428. [Abstract] [PDF]
|
|
|
|
 |
|
 C.H. Davies Revascularization for cardiogenic shock QJM, February 1, 2001; 94(2): 57 - 67. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||